Utama › Kanser Pundi Kencing › Utah
Kajian klinikal Kanser Pundi Kencing di Utah
14 kajian untuk Kanser Pundi Kencing sedang mencari peserta di lokasi di Utah.
Bandar di Utah
Teks kajian rasmi (Bahasa Inggeris)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
- Huntsman Cancer Institute ( Site 5041), Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07232602Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07061964Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Huntsman Cancer Institute - University of Utah, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Mountain Region, LLC, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05267626ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Utah, Salt Lake City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT05614739A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT06242470LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT04752722Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Intermountain Medical Center, Murray
- St George Regional Hospital Cancer Center, St. George
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT07106762Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Feb 2026 · NCT07030257Improving Care for Rural Patients With Solid Tumors
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Mengambil peserta
Umur 18 hingga 99 · Semua jantina · Dikemas kini 5 Feb 2026 · NCT04916990SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.